Carrier Screening ACT Sheet

No Mutations Detected by Carrier Screening

Cystic Fibrosis (CF)

Why Genetic Carrier Screening is Done: Carrier screening is done to identify individuals without a family history of CF or a known family mutation in the CFTR gene who may be at increased risk of having children affected with CF. (Individuals with a family history of CF should always be offered cystic fibrosis transmembrane conductance regulator (CFTR) gene testing.)

Condition Description: CF is an autosomal recessive inherited disease caused by mutations in the CFTR gene. The cystic fibrosis transmembrane conductance regulator (CFTR) protein regulates chloride transport that is important for function of lungs, upper respiratory tract, pancreas, liver, sweat glands and genitourinary tract. CF affects multiple body systems and is associated with progressive damage to respiratory and digestive systems. About 1 in 25 (~4%) Caucasians and 1% or higher in other population groups are carriers. Only the most common and severe mutations are included in carrier screening panels; therefore not all carriers are detected by screening.

YOU SHOULD TAKE THE FOLLOWING ACTIONS:

- Inform carrier of screening result and residual risk as in report.

Reproductive Implications: A negative screening test result does not exclude the possibility that one of the rarer CFTR mutations is present. Over 1500 mutations have been described in CFTR. The mutations that are recommended to be included in routine screening are relatively common and often associated with classical CF in affected individuals. Those screened should be made aware of this limitation to CF carrier screening and given their residual risk of being a carrier.

Additional Information:

Gene Tests/Gene Clinics
Genetics Home Reference
American College of Medical Genetics

Referral (local, state, regional and national):

Testing
Clinical Services
Find Genetic Services

Disclaimer: This guideline is designed primarily as an educational resource for clinicians to help them provide quality medical care. It should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. Adherence to this guideline does not necessarily ensure a successful medical outcome. In determining the propriety of any specific procedure or test, the clinician should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen. Clinicians are encouraged to document the reasons for the use of a particular procedure or test, whether or not it is in conformance with this guideline. Clinicians also are advised to take notice of the date this guideline was adopted, and to consider other medical and scientific information that become available after that date.

© American College of Medical Genetics and Genomics, 2012 (Funded in part through MCHB/HRSA/HHS grant #U22MC03957)
LOCAL RESOURCES: Insert State newborn screening program web site links

State Resource site  (insert state newborn screening program website information)

<table>
<thead>
<tr>
<th>Name</th>
<th>URL</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Local Resource Site  (insert local and regional newborn screening website information)

<table>
<thead>
<tr>
<th>Name</th>
<th>URL</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

APPENDIX: Resources with Full URL Addresses

Additional Information:
- Gene Tests/Gene Clinics  
  http://www.genetests.org/query?dz=cf
- Genetics Home Reference  
  http://ghr.nlm.nih.gov/condition=cysticfibrosis
- American College of Medical Genetics  
  http://www.acmg.net/StaticContent/StaticPages/CF_Mutation.pdf

Referral (local, state, regional and national):
- Testing  
- Clinical Services  
- Find Genetic Services  
  http://www.acmg.net/GIS/Disclaimer.aspx